GlassScriptPhysician profile
Carmen M Baybayan
NPI 1851487573
$20,495.71
in general payments reported to CMS, 2019-2025
33 companies · $3,300 in 2025
The $3,300 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,371 · 2020: $2,293 · 2021: $3,295 · 2022: $2,864 · 2023: $2,000 · 2024: $3,373 · 2025: $3,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,642 · Education: $30.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,642.12 |
| Education | $30.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,928.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,613.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $2,446.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $2,408.47 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,604.63 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $1,314.85 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $972.65 | 2022-2025 | |
| Glaxosmithkline, LLC. | $903.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $767.34 | 2023-2025 | Rexulti, Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $653.85 | 2019-2022 | |
| Abbvie INC. | $540.67 | 2019-2025 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $370.67 | 2021-2024 | |
| Pfizer INC. | $352.21 | 2019-2024 | |
| Horizon Therapeutics Plc | $332.29 | 2019-2023 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $283.86 | 2022-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $283.77 | 2025 | Fanapt |
| Lundbeck LLC | $267.55 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $261.63 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $231.08 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.03 | 2022-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $130.26 | 2022 | |
| Allergan, INC. | $122.91 | 2019-2020 | |
| Esperion Therapeutics, INC. | $93.85 | 2021-2025 | Nexletol |
| Abbott Laboratories | $72.34 | 2022-2023 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $71.85 | 2024-2025 | |
| Radius Health, INC. | $61.67 | 2020 | |
| Corcept Therapeutics | $49.56 | 2024 | Korlym |
| Astellas Pharma US INC | $46.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.53 | 2021 | |
| Dexcom, INC. | $31.19 | 2023 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.76 | 2024 | Rexulti |
| Vifor Pharma, INC. | $21.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Baybayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.